Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.47 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 3/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31485403 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL62053 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL4638950 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL905579 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL418811 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL60425 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL60847 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL2695073 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL2693658 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR | |
| SCHEMBL52689 | 1.00 | SMPD1 (0.47) | SMPD1SLC25A20TP53CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102836-A1 | Amoebicidal Compositions for Contact Lens Solutions | UNIVERSITY OF THE WEST OF SCOTLAND (GB) | 2023-03-30 | — | — | US | claimed |
| WO-2021028696-A1 | AMOEBICIDAL COMPOSITIONS FOR CONTACT LENS SOLUTIONS | UNIVERSITY OF THE WEST OF SCOTLAND (GB) | 2021-02-18 | — | — | WO | claimed |
| US-7465716-B2 | Targeted drug delivery with a hyaluronan ligand | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-16 | — | — | US | claimed |
| EP-1233754-A4 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | UNIV CALIFORNIA (US) | 2006-06-07 | — | — | EP | claimed |
| JP-2004511426-A | — | — | 2004-04-15 | — | — | JP | claimed |
| US-20030166602-A1 | A delivery vehicle low molecular weight hyaluronan ligand, glycosaminoglycan ligand for binding to antigen, with antitumor agents, or anticancer agents | SZOKA FRANCIS C (US) | 2003-09-04 | — | — | US | claimed |
| WO-2001082899-A9 | CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES | MBT MUNICH BIOTECHNOLOGY AG (DE) | 2003-05-08 | — | — | WO | claimed |
| US-20030083313-A1 | Treatment of breast cancer with a liposome mixture comprising an antineoplastic alkylphospholipid and water- or lipid-soluble antiestrogen agents | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1278512-A2 | CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES | MBT Munich Biotechnology AG (DE) | 2003-01-29 | — | — | EP | claimed |
| EP-1135193-B1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX DELBRUECK CENTRUM (DE) | 2002-10-30 | — | — | EP | claimed |
| US-20020131995-A1 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | CALIFORNIA, UNIVERSITY OF THE, REGENTS OF, THE | 2002-09-19 | — | — | US | claimed |
| EP-1233754-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | The Regents of The University of California (US) | 2002-08-28 | — | — | EP | claimed |
| US-20020034537-A1 | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | MEDIGENE ONCOLOGY GMBH (DE) | 2002-03-21 | — | — | US | claimed |
| WO-2001082899-A2 | CATIONIC DIAGNOSTIC, IMAGING AND THERAPEUTIC AGENTS ASSOCIATED WITH ACTIVATED VASCULAR SITES | MBT MUNICH BIOTECHNOLOGY AG (DE) | 2001-11-08 | — | — | WO | claimed |
| EP-1135193-A1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2001-09-26 | — | — | EP | claimed |
| WO-2001039815-A2 | TARGETED DRUG DELIVERY WITH A CD44 RECEPTOR LIGAND | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2000033917-A1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2000-06-15 | — | — | WO | claimed |
| WO-2026099586-A1 | DRY POWDER FORMULATIONS | NANOPHARM LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| EP-0230575-A2 | Medicament active against tumours, containing hexadecylphosphocholine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-08-05 | — | — | EP | disclosed |
| WO-1987003480-A2 | MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) | 1987-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102836-A1 | Amoebicidal Compositions for Contact Lens Solutions | APH1B, PHOSPHO1, UACA | SMPD1 99/4885SLC25A20 527/4885TP53 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.